| Literature DB >> 35140795 |
Na-Na Yang1, Jing-Wen Yang1, Chun-Xia Tan1, Yue-Jie Li1, Yu Wang1, Ling-Yu Qi1, Cun-Zhi Liu1.
Abstract
BACKGROUND: Postprandial distress syndrome (PDS) is accompanied by a high incidence of mood disorder. Acupuncture is an effective method in relieving dyspepsia symptoms; however, the impact of psychological status on acupuncture for PDS remains mysterious.Entities:
Year: 2022 PMID: 35140795 PMCID: PMC8820860 DOI: 10.1155/2022/1614648
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Study flow diagram.
Participant baseline characteristics.
| Characteristic | Anxiety ( | Depression ( | ||
|---|---|---|---|---|
| Anxiety patients, | Nonanxiety patients, | Depressive patients, | Nondepressive patients, | |
| Mean age (SD), | 42.3 (2.4) | 41.0 (1.4) | 41.9 (2.1) | 41.1 (1.5) |
|
| ||||
| Sex, | ||||
| Female | 21 (67.7) | 63 (75.9) | 23 (71.9) | 61 (74.4) |
| Male | 10 (32.3) | 20 (24.1) | 9 (28.1) | 21 (25.6) |
|
| ||||
| Marital status, | ||||
| Married | 24 (77.4) | 60 (72.3) | 27 (84.4) | 57 (69.5) |
| Single | 7 (22.6) | 23 (27.7) | 5 (15.6) | 25 (30.5) |
|
| ||||
| Occupation, | ||||
| Mental work | 27 (87.1) | 72 (86.7) | 31 (96.9) | 68 (82.9) |
| Manual work | 4 (12.9) | 11 (13.3) | 1 (3.1) | 14 (17.1) |
| Education (SD), | 14.7 (0.7) | 15.1 (0.3) | 15.2 (0.6) | 14.9 (0.3) |
| Mean body mass index (SD), kg/m2 | 21.5 (0.7) | 22.1 (0.4) | 22.0 (0.7) | 21.9 (0.4) |
| Mean disease duration (SD), | 66.2 (12.2) | 52.2 (5.6) | 62.8 (11.0) | 53.3 (6.0) |
|
| ||||
| Endoscopy findings, | ||||
| Normal | 0 (0) | 6 (11.8) | 4 (19.0) | 2 (3.9) |
| Chronic superficial gastritis | 14 (66.7) | 32 (62.7) | 12 (57.1) | 34 (66.7) |
| Chronic nonatrophic gastritis | 7 (33.3) | 13 (25.5) | 5 (23.8) | 15 (29.4) |
|
| ||||
|
| ||||
| Positive | 3 (10.3) | 20 (26.7) | 6 (20.7) | 18 (24.0) |
| Negative | 26 (89.7) | 55 (73.3) | 23 (79.3) | 57 (76.0) |
There was significant difference (P < 0.05) between the study groups. ⨗Data were available for 77 patients. ℥Data were available for 104 patients.
Primary outcomes in the anxiety and nonanxiety patients.
| Outcome, | Anxiety patients, | Nonanxiety patients, | Difference (95% CI) |
|
|---|---|---|---|---|
| Response rate | 24 (77.4) | 70 (84.3) | 1.6 (0.6 to 4.4) | 0.388 |
| Elimination rate | 3 (9.7) | 23 (27.7) | 3.6 (1.0 to 12.9) | 0.041 |
∔Calculated using the χ2 test. P < 0.05.
Figure 2Response rate based on overall treatment effect (a) and elimination rate of all 3 cardinal symptoms (b) at each assessment time point. Spearman's related analysis between the comorbid anxiety and the score of overall treatment effect or all 3 cardinal symptoms at week 4 (c). P < 0.05; P < 0.01.
Secondary outcomes in the anxiety and nonanxiety patients.
| Outcome, | Anxiety patients, | Nonanxiety patients, | Difference (95% CI) |
|
|---|---|---|---|---|
| Response rate | ||||
| Week 8 | 23 (74.2) | 75 (90.4) | 3.3 (1.1 to 9.7) | 0.027 |
| Week 12 | 24 (77.4) | 69 (83.1) | 1.4 (0.5 to 4.0) | 0.484 |
| Week 16 | 22 (71.0) | 64 (77.1) | 1.4 (0.5 to 3.5) | 0.498 |
|
| ||||
| Elimination rate | ||||
| Week 8 | 6 (19.4) | 26 (31.3) | 1.9 (0.7 to 5.2) | 0.206 |
| Week 12 | 7 (22.6) | 24 (28.9) | 1.6 (0.6 to 4.1) | 0.360 |
| Week 16 | 9 (29.0) | 24 (28.9) | 1.0 (0.4 to 2.5) | 0.990 |
∔Calculated using the χ2 test. P < 0.05.
Primary outcomes in the depressive and nondepressive patients.
| Outcome, | Depressive patients, | Nondepressive patients, | Difference (95% CI) |
|
|---|---|---|---|---|
| Response rate | 25 (78.1) | 68 (82.8) | 1.4 (0.5 to 3.8) | 0.552 |
| Elimination rate | 5 (15.6) | 21 (25.6) | 1.9 (0.6 to 5.4) | 0.254 |
Figure 3Response rate based on overall treatment effect (a) and elimination rate of all 3 cardinal symptoms (b) at each assessment time point. Spearman's related analysis between the comorbid depression and the score of overall treatment effect or all 3 cardinal symptoms at week 4 (c). P < 0.05.
Secondary outcomes in the depressive and nondepressive patients.
| Outcome, | Depressive patients, | Nondepressive patients, | Difference (95% CI) |
|
|---|---|---|---|---|
| Response rate | ||||
| Week 8 | 24 (75.0) | 74 (90.2) | 3.1 (1.0 to 9.1) | 0.035 |
| Week 12 | 23 (71.9) | 70 (85.4) | 2.2 (0.9 to 6.1) | 0.095 |
| Week 16 | 20 (62.5) | 65 (79.3) | 2.3 (0.9 to 5.6) | 0.065 |
|
| ||||
| Elimination rate | ||||
| Week 8 | 8 (25.0) | 24 (29.3) | 1.2 (0.4 to 3.1) | 0.649 |
| Week 12 | 6 (18.8) | 27 (32.9) | 2.1 (0.8 to 5.8) | 0.134 |
| Week 16 | 9 (28.1) | 24 (29.3) | 1.1 (0.4 to 2.6) | 0.904 |
∔Calculated using the χ2 test. P < 0.05.